-
Cancer Commun: Clinical characteristics and prognosis analysis of Chinese KRAS mutant non-small cell lung cancer patients after chemotherapy
Time of Update: 2021-11-02
Clinical studies have shown that white patients with non-small cell lung cancer with KRAS mutations have a poor prognosis after first-line chemotherapy .
Clinical studies have shown that white patients with non-small cell lung cancer with KRAS mutations have a poor prognosis after first-line chemotherapy .
-
J Thorac Oncol: Long-term efficacy of nivolumab + ipilimumab in the treatment of advanced non-small cell lung cancer
Time of Update: 2021-11-02
Compared with chemotherapy, nivolumab combined with ipilimumab can prolong the overall survival of NSCLC patients with non-small cell lung cancer ( NSCLC ) whose tumor programmed death ligand 1 (PD-L1) expression is ≥1%This article reports the results of the CheckMate 227 study, which was followed up for the shortest 4 years .
-
For small cell lung cancer!
Time of Update: 2021-11-01
Reference materials:[1] The Phase 2 clinical study of Pranabrin combined with nivolumab + ipilimumab in the treatment of third-line relapsed small cell lung cancer patients with previous immune checkpoint inhibitors failed to complete the first patient administration.
-
in the treatment of stage III non-small cell lung cancer in the form of an oral report at the 2021 European Society of Medical Oncology (ESMO) annual meeting
Time of Update: 2021-10-23
Suzhou, September 17, 2021/PRNewswire/ - CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focusing on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, today Announced that at the 2021 European Society of Medical Oncology (ESMO) annual meeting, the registered clinical study GEMSTONE-301 for the treatment of stage III non-small cell lung cancer (NSCLC) with sugarizumab was selected as a late-breaking abstract at the ESMO annual meeting.
-
Researchers build a precise prediction model for the efficacy of chemotherapy/targeted therapy for non-small cell lung cancer
Time of Update: 2021-10-21
Gao Xin's team, a researcher from the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, collaborated with Shandong Cancer Hospital to explore the predictive value of pre-treatment medical imaging information on the efficacy of chemotherapy/targeted therapy for non-small cell lung cancer .
-
16 exquisite pictures: delineation of the radiotherapy target area for locally advanced non-small cell lung cancer
Time of Update: 2021-10-20
Basic InformationDiagnosis : Poorly differentiated adenocarcinoma of the upper lobe of the right lung, stage IIIA .
Radiotherapy target area: right upper lobe mass, right hilar, mediastinal 2R, 3A, 4R, 7 lymph node drainage area .
Target delineation map of tumor precision radiotherapy [M].
-
Front Oncol: Treatment outcome of patients with extensive-stage small cell lung cancer (ED-SCLC): retrospective analysis of 9994 patients from South Korea
Time of Update: 2021-10-20
In summary, the retrospective study of the large Korean population showed that the IP regimen can significantly improve the OS and TFST of patients with ED-SCLC in the first-line treatment .
-
Cyberknife target delineation for early non-small cell lung cancer
Time of Update: 2021-10-20
Preparation for CT localization of non-small cell lung cancer A gold label was placed in the lesion 1 week before the patient was positioned .
4. Examples of non-small cell lung cancer: delineation of target areas and organs at risk4.
-
inhibitor Teppetko in the treatment of non-small cell lung cancer (NSCLC)
Time of Update: 2021-10-20
1 months; 66 patients in the liquid biopsy group The ORR rate was 48% (95% CI, 36 to 61); the ORR rate of 60 patients in the tissue biopsy group was 50% (95% CI, 37 to 63); the response rate assessed by the researchers was 56% (95% CI , 45 to 66), regardless of the previous treatment for advanced or metastatic disease, the remission rate is similar (Figure 1) .
-
effect of crizotinib on ALK rearranged non-small cell lung cancer
Time of Update: 2021-10-20
ALK rearrangement of non-small cell lung cancer ( NSCLC ) gene fusion variants may predict the prognosis of patients, but the results of previous studies are still uncertain .
-
Cancer Cell: Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Types
Time of Update: 2021-10-19
"The most exciting thing we found is that there is a rare group of stem cell-like cells in these tumors, which are closely related to the patient's prognosis," explained Charles Rudin, an internal medicine scientist at MSK.
-
of Taletrectinib in ROS1-positive non-small cell lung cancer at the CSCO annual meeting in 2021
Time of Update: 2021-10-11
("Baoyuan Pharmaceutical"), a company dedicated to the development of new types of first-in-class or best-in-class The clinical stage company of precision tumor therapy jointly announced today the interim data of the second phase trial of a new generation of ROS1/NTRK inhibitor Taletrectinib for ROS1-positive non-small cell lung cancer .
-
of taletrectinib for ROS1-positive non-small cell lung cancer at the CSCO 2021 meeting
Time of Update: 2021-10-11
Among 21 patients who were not treated with crizotinib, the confirmed objective response rate (ORR) was 90. 5% (19/21), and the disease control rate (DCR) was 90. 5% (19/21) . Among the 16 patient
-
of treated advanced non-small cell lung cancer (NSCLC) with negative driver genes
Time of Update: 2021-10-10
However, the efficacy of the PD-L1 inhibitor atezolizumab combined with the CTLA4 inhibitor ipilimumab in the treatment of treated advanced non-small cell lung cancer (NSCLC) with negative driver genes is unclear .
-
with pemetrexed + platinum-based chemotherapy in the first-line treatment of driver-gene-negative advanced non-squamous non-small cell lung cancer (NSCLC)
Time of Update: 2021-10-10
Bevacizumab or pembrolizumab combined with pemetrexed + platinum-based chemotherapy are recommended as first-line treatment for patients with advanced non-squamous non-small cell lung cancer ( NSCLC ) with negative driver genes .